Economy News – Follow-up
On Monday, shares of Novo Nordisk experienced a decline following the announcement of clinical results for CAGRISEMA, a new weight loss medication. This innovative drug demonstrated efficacy in assisting adults grappling with obesity and type 2 diabetes, achieving an average weight loss of 15.7% after a treatment duration of 68 weeks.
By 11:22 am London time, the stock price of Novo Nordisk had dropped by 5.4%.
Novo Nordisk, known for its widely recognized weight management product Wigofi, had previously anticipated a 25% weight reduction in patients using CAGRISEMA. Notably, earlier clinical trials published in December indicated a weight loss of 22.7% among participants.
CAGRISEMA is currently under development as a treatment option for adults with obesity or excess weight and is also being explored as a potential therapy for individuals with type 2 diabetes. The company plans to submit an application for regulatory approval in the first quarter of 2026.
Stay Updated: For more news, subscribe to our channel on Telegram.
